Lyfgenia (lovotibeglogene autotemcel) 비교

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTCurated CoreFDAApproved lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111) bluebird bio·βA-T87Q-globin (lentiviral) 2 trials

Overview Program	Lyfgenia (lovotibeglogene autotemcel)
Overview Company	bluebird bio
Overview Modality	CGT
Overview Target	βA-T87Q-globin (lentiviral)
Overview Indication	Sickle cell disease with recurrent vaso-occlusive events
Overview Phase	APPROVED
Overview Status	APPROVED
Overview Content status	Curated Core
Overview Data Confidence	Data Confidence · High
Overview Development Signal	Development Signal · Established
Overview Approval status	FDA approved

Positioning Key differentiator	Gene addition of anti-sickling globin vs CRISPR HbF induction
Positioning Known limitation	bypassing such limitations
Positioning Development positioning	Lentiviral alternative to Casgevy in SCD

Technology Vector	Lentiviral vector

MoA Mechanism	Lovotibeglogene autotemcel adds functional β-globin gene via lentiviral vector to autologous CD34+ cells, producing anti-sickling HbAT87Q in sickle cell disease.
MoA Biomarker	HbAT87Q, VOC, TCD velocities.

PK/PD Animal (cat.)	Unknown
PK/PD Experiment	pd

Toxicology Major finding	Hematologic malignancy risk (boxed warning); conditioning toxicities

Clinical Safety signal	Hematologic malignancy risk (boxed warning); conditioning toxicities
Clinical Result source	ClinicalTrials.gov NCT02140554
Clinical Program phase	APPROVED
Clinical Trial activity	1 recruiting · 1 completed
Clinical Trial ref	NCT02140554

선택됨 (1/5)

추천 · 인기 프로그램

최대 5개 선택 · 전체 25+ 프로그램은 검색으로 찾을 수 있습니다. ADC 목록 →

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTCurated CoreFDAApproved lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111) bluebird bio·βA-T87Q-globin (lentiviral) 2 trials

Overview Program	Lyfgenia (lovotibeglogene autotemcel)
Overview Company	bluebird bio
Overview Modality	CGT
Overview Target	βA-T87Q-globin (lentiviral)
Overview Indication	Sickle cell disease with recurrent vaso-occlusive events
Overview Phase	APPROVED
Overview Status	APPROVED
Overview Content status	Curated Core
Overview Data Confidence	Data Confidence · High
Overview Development Signal	Development Signal · Established
Overview Approval status	FDA approved

Positioning Key differentiator	Gene addition of anti-sickling globin vs CRISPR HbF induction
Positioning Known limitation	bypassing such limitations
Positioning Development positioning	Lentiviral alternative to Casgevy in SCD

Technology Vector	Lentiviral vector

MoA Mechanism	Lovotibeglogene autotemcel adds functional β-globin gene via lentiviral vector to autologous CD34+ cells, producing anti-sickling HbAT87Q in sickle cell disease.
MoA Biomarker	HbAT87Q, VOC, TCD velocities.

PK/PD Animal (cat.)	Unknown
PK/PD Experiment	pd

Toxicology Major finding	Hematologic malignancy risk (boxed warning); conditioning toxicities

Clinical Safety signal	Hematologic malignancy risk (boxed warning); conditioning toxicities
Clinical Result source	ClinicalTrials.gov NCT02140554
Clinical Program phase	APPROVED
Clinical Trial activity	1 recruiting · 1 completed
Clinical Trial ref	NCT02140554